Apellis Pharmaceuticals Inc (NASDAQ:APLS) has received a consensus recommendation of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $41.78.

APLS has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $54.00 price target (up from $50.00) on shares of Apellis Pharmaceuticals in a research report on Monday, November 25th. Credit Suisse Group assumed coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, November 5th. They set a “neutral” rating and a $33.00 price target on the stock. ValuEngine cut Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research upgraded Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, November 25th. Finally, Wedbush started coverage on Apellis Pharmaceuticals in a research note on Wednesday, November 27th. They set an “underperform” rating and a $23.00 target price for the company.

In other Apellis Pharmaceuticals news, COO Pascal Deschatelets sold 42,460 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $24.82, for a total value of $1,053,857.20. Also, CEO Cedric Francois sold 5,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $26.59, for a total transaction of $132,950.00. In the last three months, insiders sold 57,460 shares of company stock worth $1,464,957. 10.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. grew its stake in Apellis Pharmaceuticals by 160.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,300 shares of the company’s stock worth $33,000 after purchasing an additional 800 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Apellis Pharmaceuticals by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 75,326 shares of the company’s stock valued at $1,815,000 after buying an additional 909 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Apellis Pharmaceuticals by 59.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,944 shares of the company’s stock valued at $75,000 after buying an additional 1,099 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Apellis Pharmaceuticals in the 2nd quarter valued at $39,000. Finally, Swiss National Bank grew its position in shares of Apellis Pharmaceuticals by 2.1% in the 2nd quarter. Swiss National Bank now owns 81,100 shares of the company’s stock valued at $2,055,000 after buying an additional 1,700 shares during the last quarter. 61.68% of the stock is owned by institutional investors and hedge funds.

Shares of Apellis Pharmaceuticals stock traded up $2.02 during mid-day trading on Thursday, reaching $28.88. 62,975 shares of the stock traded hands, compared to its average volume of 539,559. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 1.09. Apellis Pharmaceuticals has a fifty-two week low of $12.16 and a fifty-two week high of $33.18. The stock has a market capitalization of $1.73 billion, a PE ratio of -12.26 and a beta of 0.64. The business has a 50-day moving average of $28.27 and a 200 day moving average of $26.08.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($1.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.09). On average, equities research analysts expect that Apellis Pharmaceuticals will post -4.09 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

See Also: What is Green Investing?

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.